M1329 Pts act pvd 2 wks 8 wks
Also known as: active proliferative retinopathy, PVD active, neovascularization
Patients with active proliferative retinopathy in the 2 weeks to 8 weeks timeframe. Documents patients with advanced retinal disease requiring intensive monitoring.
In Plain Language
severe diabetic eye disease; aggressive eye disease
Clinical Context
Retinal disease quality measure tracking patients with active neovascularization and proliferative changes requiring frequent monitoring and treatment.
RVU Information
CPT M1329 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
M-codes cover quality measures and performance reporting. They are used in value-based care programs to track whether specific clinical actions were taken. Documentation must support that the measured action was performed or a valid exclusion applies.
Specialties
Frequently Asked Questions
What is CPT code M1329?
CPT M1329 (Pts act pvd 2 wks 8 wks) is a M Codes code. Patients with active proliferative retinopathy in the 2 weeks to 8 weeks timeframe. Documents patients with advanced retinal disease requiring intensive monitoring.
Is M1329 covered by insurance?
M1329 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Retinal disease quality measure tracking patients with active neovascularization and proliferative changes requiring frequent monitoring and treatment.
When is CPT M1329 used?
Retinal disease quality measure tracking patients with active neovascularization and proliferative changes requiring frequent monitoring and treatment.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.